Ghanadian R, Puah C M
J Endocrinol. 1981 Feb;88(2):255-62. doi: 10.1677/joe.0.0880255.
The relationship between the concentrations of oestradiol, testosterone, dihydrotestosterone (DHT) and 5 alpha-androstane-3 alpha, 17 beta-diol in circulating blood and prostatic tissues was studied in patients with benign prostatic hypertrophy (BPH) and carcinoma of the prostate. All steroids were measured by radioimmunoassay. In patients with BPH the tissue concentrations of oestradiol, testosterone, DHT and 5 alpha-androstane-3 alpha, 17 beta-diol expressed per kg wet weight were 228.6 +/- 7.4 (S.E.M.) pmol, 1.29 +/- 0.06 nmol, 25.61 +/- 1.15 nmol and 1.43 +/- 0.10 nmol respectively. The corresponding values for carcinomatous tissues were 380.1 +/- 19.4 pmol, 7.20 +/- 1.10 nmol, 12.32 +/- 1.56 nmol and 1.99 +/- 0.32 nmol. Significant differences (t-test) were found between the mean concentrations of oestradiol (P less than 0.001), testosterone (P less than 0.001), DHT (P less than 0.001) and 5 alpha androstane-3 alpha, 17 beta-diol (P less than 0.05) in prostatic tissues of these two groups of patients. Significant negative correlations were observed between the tissue concentrations of oestradiol and DHT (r = -0.49, P less than 0.05) and between oestradiol and 5 alpha-androstane-3 alpha,17 beta-diol (r = -0.44, P less than 0.05) in BPH but not in malignant tissues. The plasma concentrations of oestradiol, testosterone, DHT and 5 alpha-androstane-3 alpha, 17 beta-diol in patients with BPH were 147.4 +/- 6.9 pmol/l, 18.4 +/- 1.2 nmol/l, 2.6 +/- 0.2 nmol/l and 0.84 +/- 0.04 nmol/ respectively. The corresponding values for patients with carcinoma of the prostate were 145.5 +/- 17.0 pmol/l, 17.3 +/- 2.4 nmol/l, 2.0 +/- 0.3 nmol/l and 0.56 +/- 0.06 nmol/l respectively. The mean plasma 5 alpha-androstane-3 alpha, 17 beta-diol was found to be significantly higher in patients with BPH (P less than 0.01) than with carcinoma. No significant correlations were found between the tissue concentrations of these steroids and the corresponding plasma values, which suggested that their metabolism and accumulation in prostatic tumours are independent of their plasma concentrations.
在良性前列腺增生(BPH)患者和前列腺癌患者中,研究了循环血液和前列腺组织中雌二醇、睾酮、双氢睾酮(DHT)以及5α-雄甾烷-3α,17β-二醇的浓度之间的关系。所有类固醇均通过放射免疫测定法进行测量。在BPH患者中,每千克湿重的组织中雌二醇、睾酮、DHT以及5α-雄甾烷-3α,17β-二醇的浓度分别为228.6±7.4(标准误)pmol、1.29±0.06 nmol、25.61±1.15 nmol和1.43±0.10 nmol。癌组织的相应值分别为380.1±19.4 pmol、7.20±1.10 nmol、12.32±1.56 nmol和1.99±0.32 nmol。两组患者前列腺组织中雌二醇(P<0.001)、睾酮(P<0.001)、DHT(P<0.001)以及5α-雄甾烷-3α,17β-二醇(P<0.05)的平均浓度之间存在显著差异(t检验)。在BPH患者的组织中,观察到雌二醇与DHT之间(r = -0.49,P<0.05)以及雌二醇与5α-雄甾烷-3α,17β-二醇之间(r = -0.44,P<0.05)存在显著负相关,但在恶性组织中未观察到。BPH患者血浆中雌二醇、睾酮、DHT以及5α-雄甾烷-3α,17β-二醇的浓度分别为147.4±6.9 pmol/L、18.4±1.2 nmol/L、2.6±0.2 nmol/L和0.84±0.04 nmol/L。前列腺癌患者的相应值分别为145.5±17.0 pmol/L、17.3±2.4 nmol/L、2.0±0.3 nmol/L和0.56±0.06 nmol/L。发现BPH患者血浆中5α-雄甾烷-3α,17β-二醇的平均浓度显著高于前列腺癌患者(P<0.01)。这些类固醇的组织浓度与相应的血浆值之间未发现显著相关性,这表明它们在前列腺肿瘤中的代谢和积累与其血浆浓度无关。